Description du projet
Un appareil portable de nouvelle génération pour les athlètes
Les appareils de santé portables sont une technologie émergente qui modifie l’approche de la surveillance médicale. En permettant un suivi médical autonome et une gestion proactive de la santé, les athlètes se tournent également vers des capteurs portables pour surveiller leurs performances, leurs blessures et leur temps de récupération. Le projet Smart Tracker, financé par l’UE, commercialise le pack Caura, le premier détecteur moléculaire qui mesure le lactate et le glucose en temps réel pour révéler la signature moléculaire du corps. Il fournit aux athlètes à l’entraînement des informations précieuses sur les performances de leur corps pour éviter l’épuisement. La surveillance non invasive, sans fil et continue du glucose et du lactate permet aux athlètes d’identifier le régime qui fonctionne le mieux et le moment optimal pour s’entraîner. Le pack Caura utilise la nouvelle technologie de microaiguille, un détecteur numérique rentable et des algorithmes sophistiqués d’apprentissage automatique.
Objectif
Wearable biosensor systems for fitness and health monitoring have become popular in the last years, however, there is no
wearable technology currently available for accurately monitor key biometrics that directly reflect one’s body performance
(i.e. glucose and lactate) with clinical precision. In turn, Caura project aims at providing the first molecular tracker which
unlocks anyone’s molecular signature. It will give instant and real-time feedback on lifestyle and health, while providing
unmatched training insights and effective dietary plans through non-invasive, wireless and continuous glucose and lactate
monitoring. The invention relies on their cutting-edge microneedle technology, a cost-effective digital tracker plus
sophisticated machine learning algorithms allowing accurate and real-time glucose and lactate measurements for the first
time on the individual’s skin and under free living conditions. Caura will result on added value for high-quality wearables,
improving athletic performance and sport medicine by enabling ubiquitous monitoring of those biometrics. Other valuable
novelties are its reduced cost and dimensions compared to the available options. These advantages make Caura a
disruptive solution with great potential for commercial success in the growing wearables market (€285B by 2022, CAGR
12.5%), representing a core source of growth for the company and consolidating the Company position in the bio-sensing
sector. The Company will conduct a feasibility study and a business plan analyzing the technical, commercial and financial
aspects required to ensure the market launch. Being glucose and lactate important vital parameters also involved in some of
the biggest health issues (e.g. diabetes, obesity etc.), Caura will transition from simple recreational tracker to life-changing
tool focusing on individual’s lifestyle and health, enabling for the necessary transformation towards a person-centred
preventive health care system.
Champ scientifique
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensors
- natural sciencescomputer and information sciencesinternetinternet of things
- social scienceseconomics and businessbusiness and managementbusiness models
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
- medical and health scienceshealth sciencesnutritionobesity
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
SW1P 2QW LONDON
Royaume-Uni
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.